Phase II study to examine efficacy prediction of Regorafenib with FDG-PET/CT in patients with treatment-refractory metastatic colorectal cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms JACCRO CC-12
- 15 Nov 2016 Planned End Date changed from 31 Oct 2019 to 31 Mar 2017.
- 15 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Results evaluating metabolic response (n=17, From November 2014 to March 2016) presented at the 41st European Society for Medical Oncology Congress.